Works by Gill, Jasvinder

Results: 17

An exploratory analysis of the cost‐effectiveness of insulin glargine 300 units/mL versus insulin glargine 100 units/mL over a lifetime horizon using the BRAVO diabetes model.

Published in:

Diabetic Medicine, 2024, v. 41, n. 5, p. 1, doi. 10.1111/dme.15303

By:

Shao, Hui;
Shi, Lizheng;
Fonseca, Vivian;
Alsaleh, Abdul Jabbar Omar;
Gill, Jasvinder;
Nicholls, Charlie

Publication type:

Article

Cost‐effectiveness analysis of once‐daily insulin glargine 300 U/mL versus insulin degludec 100 U/mL using the BRAVO diabetes model.

Published in:

Diabetic Medicine, 2023, v. 40, n. 9, p. 1, doi. 10.1111/dme.15112

By:

Shao, Hui;
Shi, Lizheng;
Fonseca, Vivian;
Alsaleh, Abdul Jabbar Omar;
Gill, Jasvinder;
Nicholls, Charlie

Publication type:

Article

Treatment persistence, adherence and healthcare resource utilisation for iGlarLixi versus basal–bolus insulin or premixed insulin in older adult ethnic minorities with type 2 diabetes: SoliEthnicity study.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 795, doi. 10.1111/dom.16075

By:

Umpierrez, Guillermo;
Gill, Jasvinder;
Hood, David;
Li, Xuan;
Núñez, Ana

Publication type:

Article

Real‐world outcomes of addition of insulin glargine 300 U/mL (Gla‐300) to glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy in people with type 2 diabetes: The DELIVER‐G study.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 8, p. 1617, doi. 10.1111/dom.14739

By:

Bailey, Timothy S.;
Gill, Jasvinder;
Jones S., Merwyn;
Shenoy, Laxmi;
Nicholls, Charlie;
Westerbacka, Jukka

Publication type:

Article

Cover Image, Volume 22, Issue 11.

Published in:

Diabetes, Obesity & Metabolism, 2020, v. 22, n. 11, p. 1, doi. 10.1111/dom.14229

By:

Meneghini, Luigi F.;
Sullivan, Sean D.;
Oster, Gerry;
Busch, Robert;
Cali, Anna M. G.;
Dauchy, Arnaud;
Gill, Jasvinder;
Bailey, Timothy S.

Publication type:

Article

A pragmatic randomized clinical trial of insulin glargine 300 U/ mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study.

Published in:

Diabetes, Obesity & Metabolism, 2020, v. 22, n. 11, p. 2004, doi. 10.1111/dom.14152

By:

Meneghini, Luigi F.;
Sullivan, Sean D.;
Oster, Gerry;
Busch, Robert;
Cali, Anna M. G.;
Dauchy, Arnaud;
Gill, Jasvinder;
Bailey, Timothy S.

Publication type:

Article

Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trial.

Published in:

Diabetes, Obesity & Metabolism, 2020, v. 22, n. 11, p. 1995, doi. 10.1111/dom.14116

By:

Meneghini, Luigi;
Blonde, Lawrence;
Gill, Jasvinder;
Dauchy, Arnaud;
Bacevicius, Andrius;
Strong, Jodi;
Bailey, Timothy S.

Publication type:

Article

Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring.

Published in:

Diabetes, Obesity & Metabolism, 2019, v. 21, n. 8, p. 1906, doi. 10.1111/dom.13751

By:

Pettus, Jeremy;
Gill, Jasvinder;
Paranjape, Sachin;
Stewart, John;
Malla, Shilpy;
Edelman, Steven;
Bergenstal, Richard M.;
Bode, Bruce

Publication type:

Article

Post Hoc Analysis Evaluating the Impact of Antihyperglycemic Background Therapies on Attainment of A1C Targets Without Hypoglycemia in the ACHIEVE Control Pragmatic, Real-Life Study.

Published in:

Diabetes Spectrum, 2021, v. 34, n. 4, p. 407, doi. 10.2337/ds20-0079

By:

Bailey, Timothy S.;
Evenou, Pierre;
Gill, Jasvinder;
Berhanu, Paulos;
Raymond, Romain;
Strong, Jodi;
Wright Jr., Eugene E.

Publication type:

Article

Improved Treatment Engagement Among Patients with Diabetes Treated with Insulin Glargine 300 U/mL Who Participated in the COACH Support Program.

Published in:

Diabetes Therapy, 2018, v. 9, n. 5, p. 2143, doi. 10.1007/s13300-018-0501-6

By:

Goldman, Jennifer D.;
Gill, Jasvinder;
Horn, Tony;
Reid, Timothy;
Strong, Jodi;
Polonsky, William H.

Publication type:

Article

Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)

Published in:

Clinical Diabetes, 2023, v. 41, n. 3, p. 425, doi. 10.2337/cd22-0096

By:

Edelman, Steven;
Goldman, Jennifer;
Malone, Daniel C.;
Preblick, Ronald;
Munaga, Kovida;
Li, Xuan;
Gill, Jasvinder;
Gangi, Sumana

Publication type:

Article

105-LB: Real-World Outcomes of Addition of Insulin Glargine 300 U/mL (Gla-300) to GLP-1RA Therapy in People with Type 2 Diabetes (PWD2): The DELIVER-G Study.

Published in:

Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-105-LB

By:

BAILEY, TIMOTHY S.;
WESTERBACKA, JUKKA;
NICHOLLS, CHARLIE;
GILL, JASVINDER;
JONES S, MERWYN;
SHENOY, LAXMI

Publication type:

Article

103-LB: Real-World Persistence, Adherence, Health Care Resource Utilization, and Costs in People with Type 2 Diabetes (T2D) Switching from Basal Insulin (BI) to Second-Generation BI (Insulin Glargine 300 U/mL [Gla-300]) vs. First-Generation BI (Insulin Glargine 1

Published in:

Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-103-LB

By:

WRIGHT, EUGENE;
GILL, JASVINDER;
HUSE, SAMUEL;
LI, XUAN;
REID, TIMOTHY;
ZHOU, FANG L.

Publication type:

Article

1038-P: Insulin Glargine 300 U/ml (Gla-300) vs. First-Generation Standard-of-Care Basal Insulin Analogs (SOC-BI) in Insulin-Naïve Patients with Type 2 Diabetes (T2D): Impact of Renal Function on the Outcomes of the Randomized Pragmatic Real-Life Achieve Control S

Published in:

Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1038-P

By:

MENEGHINI, LUIGI;
CHENG, ALICE;
EVENOU, PIERRE;
GILL, JASVINDER;
MOHAMED, AYAD;
UMPIERREZ, GUILLERMO E.

Publication type:

Article

1087-P: A Randomized Pragmatic Real-World Clinical Trial Comparing Insulin Glargine 300 U/mL (Gla-300) with Standard of Care First-Generation Basal Insulins (SoC-BIs) in Insulin-Naïve Patients with Type 2 Diabetes: Twelve-Month Analysis of the ACHIEVE Control Study

Published in:

Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1087-P

By:

MENEGHINI, LUIGI;
GILL, JASVINDER;
DAUCHY, ARNAUD;
BACEVICIUS, ANDRIUS;
STRONG, JODI;
BAILEY, TIMOTHY S.

Publication type:

Article

Expression of Voltage-Gated Calcium Channels in Tumor Cell Lines of Neuroectodermal or Other Origin.

Published in:

Annals of the New York Academy of Sciences, 1988, v. 540, n. 1, p. 389, doi. 10.1111/j.1749-6632.1988.tb27110.x

By:

LANG, BETHAN;
NAGVEKAR, NITA;
GILL, JASVINDER;
VINCENT, ANGELA;
NEWSOM-DAVIS, JOHN

Publication type:

Article

Much Ado About Nothing? A Real-World Study of Patients with Type 2 Diabetes Switching Basal Insulin Analogs.

Published in:

Advances in Therapy, 2014, v. 31, n. 5, p. 539, doi. 10.1007/s12325-014-0120-1

By:

Wei, Wenhui;
Zhou, Steve;
Miao, Raymond;
Pan, Chunshen;
Xie, Lin;
Baser, Onur;
Gill, Jasvinder

Publication type:

Article